The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

A Pilot Study Of The ALPFA Benign Prostatic Hyperplasia (BPH) Pulsed Field Ablation (PFA) System

NCT06965582 ·Status: ENROLLING_BY_INVITATION ·Phase: NA

Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms

NCT01021332 ·Status: COMPLETED ·Phase: PHASE3

Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

NCT02245555 ·Status: COMPLETED

Real World Data on Management of Male LUTS

NCT03075449 ·Status: COMPLETED

A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).

NCT02431754 ·Status: COMPLETED ·Phase: PHASE4

Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS

NCT01589263 ·Status: COMPLETED ·Phase: PHASE2

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

NCT01939184 ·Status: COMPLETED ·Phase: PHASE2

Clinical Trial in Males With BPH (Enlarged Prostate)

NCT00029822 ·Status: COMPLETED ·Phase: PHASE3

Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms

NCT02245490 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia

NCT00284518 ·Status: COMPLETED ·Phase: PHASE2

Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker

NCT00680680 ·Status: COMPLETED ·Phase: NA

The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients

NCT00696761 ·Status: COMPLETED ·Phase: PHASE4

Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT00918034 ·Status: COMPLETED ·Phase: PHASE2

ALF-ONE : ALFuzosin ONcE Daily

NCT00280605 ·Status: COMPLETED ·Phase: PHASE4

Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms

NCT02715024 ·Status: COMPLETED ·Phase: PHASE4

Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression

NCT01716104 ·Status: COMPLETED ·Phase: PHASE3

Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT06051383 ·Status: COMPLETED ·Phase: NA

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT00435448 ·Status: TERMINATED ·Phase: PHASE3

Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia

NCT02106182 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation

NCT02180789 ·Status: COMPLETED ·Phase: PHASE4

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

NCT00507455 ·Status: COMPLETED ·Phase: PHASE2

FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)

NCT02244294 ·Status: COMPLETED ·Phase: PHASE2

MEN STUDY (ESTUDIO MEN) Quality of Life in Patients With BPH and Nocturia Before and After Tamsulosin Ocas® Treatment

NCT00885027 ·Status: COMPLETED

(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia

NCT05236634 ·Status: UNKNOWN ·Phase: NA

Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH

NCT00347061 ·Status: COMPLETED ·Phase: PHASE3